Novartis sells phase 3 rare disease drug to Pharming | Fierce Biotech
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
It Paid Doctors Kickbacks. Now, Novartis Will Pay a $678 Million Settlement. - The New York Times
Novartis offre à Sandoz son autonomie et une cotation sur SIX | Radio Lac
Moving Away from Asthma and COPD, Novartis Hones in on 20 Approvals by 2026 | BioSpace
Novartis' Cosentyx receives MHRA approval for two types of juvenile idiopathic arthritis - PMLiVE
Novartis - YouTube
Novartis CEO Targets 20 Key Drugs as Potential Blockbusters - DCAT Value Chain Insights
Novartis chief fights to restore faith - SWI swissinfo.ch
Novartis Logo and symbol, meaning, history, PNG, brand
Alcon becomes a separately traded standalone company | Novartis
Novartis shares suffer as latest sales and earnings dip
Novartis to prioritise U.S. market, unfazed by drug pricing pushback | Reuters
Rick Carlson - Oncology Care Consultant (Breast Cancer) - Novartis | LinkedIn
Novartis is shutting down Colorado plant, laying off 400 employees after overestimating gene therapy demand | Fierce Pharma
Novartis to spin off generics business Sandoz next year | Reuters
Two Children Die After Receiving Novartis Gene Therapy | The Scientist Magazine®
